13 results about "Plasmalogen" patented technology

This invention discloses a quantitative method for phospholipids, comprising: a sample preparation step, wherein a sample containing protein and phospholipids is mixed with Schiff reagent to obtain a sample for testing; a control sample preparation step, wherein the sample is mixed with a solvent of Schiff reagent to obtain a control sample; a measurement step, wherein the degree of a first optical property of the sample for testing and the degree of an optical property of the control sample are measured after the reaction of the aldehyde formed by the vinyl ether bond of phospholipids with Schiff reagent; and a determination step, wherein a correction degree obtained by correcting the degree of the first optical property using the degree of the optical property of the control sample is compared with the degree of a second optical property of the standard sample to determine the concentration of phospholipids in the sample, wherein the standard sample contains Schiff reagent and phospholipids of known concentration, and the degree of the second optical property is the degree of reaction of the Schiff reagent with the aldehyde formed by the vinyl ether bond of phospholipids.

A protein includes an amino acid sequence selected from the group consisting of the following (a), (b), (c), and (d): (a) an amino acid sequence of SEQ ID NO:1; (b) an amino acid sequence having a sequence identity of not less than 80% to the amino acid sequence of SEQ ID NO:1; (c) an amino acid sequence of SEQ ID NO:2; and (d) an amino acid sequence having a sequence identity of not less than 80% to the amino acid sequence of SEQ ID NO:2, the protein having plasmalogen synthesis activity in a bacterium that expresses the protein.

This plasmalogen detection method comprises: a sample preparation step for mixing a Schiff's reagent and a specimen containing a plasmalogen to obtain a sample; a reaction step for reacting the plasmalogen in the sample with the Schiff's reagent; and a contact step for bringing at least some of the sample reacted in the reaction step into contact with a stationary phase containing a silica gel.

This disclosure relates to synthetic methods of making bioactive in vivo precursors to plasmalogen compounds and salts thereof and to making plasmalogens and their derivatives and salts thereof. This disclosure also relates to chemical precursors to bioactive compounds and salts thereof. This disclosure further relates to compositions comprising one or more compounds of this disclosure and the use of such compositions in preparing compounds useful in methods of treating diseases and conditions that are beneficially treated by administering plasmalogens or their derivatives or precursors that are transformed in vivo to plasmalogens.

The invention belongs to the technical field of biological medicines, and particularly relates to application of EPA (eicosapentaenoic acid) plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy, which is characterized by treating diabetic nephropathy mouse models induced by high fat diet and streptozotocin and having insulin resistance and hyperglycemia accompanied by kidney lipid accumulation and glomerular filtration rate reduction, and particularly relates to application of EPA plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy. The treatment effect of the EPA plasmalogen on the diabetic nephropathy is observed; results show that the EPA plasmalogen has obvious effects of improving kidney functions and kidney ectopic lipid deposition on diabetic nephropathy mice induced by high fat diet and streptozotocin, and also has the effects of reducing blood sugar, improving blood fat, reducing insulin resistance and the like. The EPA plasmalogen is used for intervening the diabetic nephropathy for the first time, and an important basis is provided for clinically treating the diabetic nephropathy by using the EPA plasmalogen.

This disclosure relates to synthetic methods of making bioactive in vivo precursors to plasmalogen compounds and salts thereof and to making plasmalogens and their derivatives and salts thereof. This disclosure also relates to chemical precursors to bioactive compounds and salts thereof. This disclosure further relates to compositions comprising one or more compounds of this disclosure and the use of such compositions in preparing compounds useful in methods of treating diseases and conditions that are beneficially treated by administering plasmalogens or their derivatives or precursors that are transformed in vivo to plasmalogens.

Disclosed is a muscle enhancer which contains plasmalogen as an active ingredient.

This disclosure relates to methods of using certain precursor compounds such as lysoalkylphosphatidylcholines, (LPC(O)s) to increase the levels of plasmalogens in the subject to provide improved health outcomes. More specifically, this disclosure relates to the use of the precursor compounds to treat liver diseases and controlling weight.

This invention discloses an adiponectin enhancer, which contains phospholipid acetal as an active ingredient.

It is a composition for enhancing immune function, or a composition for activating natural killer cells, comprising plasmalogen.

A method for promoting collagen production, which includes administering to a human a composition containing plasmalogen. The plasmalogen can be a plasmalogen extracted from animal tissues. The composition containing the plasmalogen can be administered to the human as an oral agent or as a parenteral agent. Parenteral agents include external agent and injection agents.

The invention relates to engineering saccharomycetes for synthesizing plasmalogen as well as a construction method and application thereof, and belongs to the technical field of microbial engineering, chassis cells of the engineering saccharomycetes are yarrowia lipolytica, and CarF genes of aldolase are integrated at URA sites of yarrowia lipolytica genes. The nucleotide sequence of the gene CarF is shown as SEQ ID NO: 1 or a degenerate sequence of the SEQ ID NO: 1, or a base sequence having more than 80% of sequence identity with the SEQ ID NO: 1 and a corresponding amino acid sequence of the base sequence. According to the engineering saccharomycetes PG01, the yield of plasmalogen is 0.21 mg / g protein and is increased by one time compared with the yield of wild saccharomycetes.

The invention discloses application of mussel plasmalogen in preparation of a product for improving activity of lithocholic acid synthase. The mussel plasmalogen comprises mussel plasmalogen phosphatidylethanolamine and / or mussel plasmalogen phosphatidylserine. The mussel plasmalogen comprises mussel plasmalogen phosphatidylethanolamine and The mussel plasmalogen promotes the biosynthesis of lithocholic acid by enhancing the activity of lithocholic acid synthetase, significantly reduces the content of a lithocholic acid synthesis precursor and significantly improves the lithocholic acid level.